Evidence map›Paper›PMID 33609609›Full record

ArticleCancer letters2021

Loss of CD73 shifts transforming growth factor-β1 (TGF-β1) from tumor suppressor to promoter in endometrial cancer.

Katherine C Kurnit, Ashley Draisey, Rebecca C Kazen, Christine Chung, Luan H Phan, Jerry B Harvey, Jiping Feng, SuSu Xie, Russell R Broaddus, Jessica L Bowser

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Adenosinergic Signalling in Cervical Cancer Microenvironment.Expert reviews in molecular medicine · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Katherine C KurnitDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Ashley DraiseyUniversity of Northern Iowa, Cedar Falls, IA, USA; CPRIT/CURE Summer Research Experience, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca C KazenUniversity of Colorado at Boulder, Boulder, CO, USA; CPRIT/CURE Summer Research Experience, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christine ChungDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luan H PhanUniversity of Texas McGovern Medical School, Houston, TX, USA.
Jerry B HarveyColumbia University, New York, NY, USA.
Jiping FengDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
SuSu XieDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Russell R BroaddusDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Jessica L BowserDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: jessica_bowser@med.unc.edu.
The University of Texas MD Anderson Cancer Center · USUniversity of North Carolina at Chapel Hill · USColumbia University · USThe University of Texas Health Science Center at Houston · USUniversity of Chicago · USUniversity of Northern Iowa · US

Funding

Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0M
Center for Clinical and Translational SciencesTL1RR024147 · NCRR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2006 to 2011
$2.3M
NCI NIH HHS P50 CA098258NCRR NIH HHS TL1 RR024147
6 · The paper itself

Abstract

In many tumors, CD73 (NT5E), a rate-limiting enzyme in adenosine biosynthesis, is upregulated by TGF-β and drives tumor progression. Conversely, CD73 is downregulated in endometrial carcinomas (EC) despite a TGF-β-rich environment. Through gene expression analyses of normal endometrium samples of the uterine cancer TCGA data set and genetic and pharmacological studies, we discovered CD73 loss shifts TGF-β1 from tumor suppressor to promoter in EC. TGF-β1 upregulated CD73 and epithelial integrity in vivo in the normal endometrium and in vitro in early stage EC cells. With loss of CD73, TGF-β1-mediated epithelial integrity was abrogated. EC cells developed TGF-β1-mediated stress fibers and macromolecule permeability, migration, and invasion increased. In human tumors, CD73 is downregulated in deeply invasive stage I EC. Consistent with shifting TGF-β1 activity, CD73 loss increased TGF-β1-mediated canonical signaling and upregulated cyclin D1 (CCND1) and downregulated p21 expression. This shift was clinically relevant, as CD73

Indexed as

5'-NucleotidaseAdenosineAdultAgedAnimalsCell DifferentiationCell Line, TumorEndometrial NeoplasmsFemaleGPI-Linked ProteinsHumansMiceMice, Inbred C57BLMiddle AgedNeoplasm StagingTransforming Growth Factor beta15'-NucleotidaseAdenosineGPI-Linked ProteinsNT5E protein, humanTGFB1 protein, humanTransforming Growth Factor beta1Tumor Suppressor ProteinsAdenosineCD73Endometrial cancerTGF-βTumor suppressor

Identifiers

PMID33609609
PMCPMC9812391
OpenAlexW3132426651

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.